Association of advanced vasculopathy and transforming growth factor-beta1 gene expression with immunoglobulin A nephropathy progression

Nephrology Dialysis Transplantation

Volumn 26, Issue 2, 2011, Pages 573-579

  Brabcova, Irena ^a   Tesar, Vladimir ^b   Honsova, Eva ^a   Lodererova, Alena ^a   Novotna, Eva ^a   Maixnerova, Dita ^b   Merta, Miroslav ^b   Brgelova, Marcela ^a   Hribova, Petra ^a   Skibova, Jelena ^a   Zadrazil, Josef ^c   Maly, Jan ^a   Viklicky, Ondrej ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

cytokines; gene expression; IgA nephropathy; interstitial infiltrate; vasculopathy

Indexed keywords

CHEMOKINE; CYTOKINE; OSTEOGENIC PROTEIN 1; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; B LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; GENE; GENE EXPRESSION; HISTOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEINURIA; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; T LYMPHOCYTE; VASCULAR DISEASE;

EID: 79551493014     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq423     Document Type: Article

References (23)

1. Julian BA, Novak J. IgA nephropathy: an update. Curr Opin Nephrol Hypertens 2004; 13: 171-179
2. D'Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis 2000; 36: 227-237
3. Viklicky O, Hribova P, Volk HD et al. Molecular phenotypes of acute rejection predict renal graft prognosis. J Am Soc Nephrol 2010; 21: 173-180
4. Itadani H, Mizuarai S,Kotani H. Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics 2008; 9: 349-360
5. Schmid H, Henger A, Kretzler M. Molecular approaches to chronic kidney disease. Curr Opin Nephrol Hypertens 2006; 15: 123-129
6. Rovin BH, McKinley AM, Birmingham DJ. Can we personalize treatment for kidney diseases? Clin J Am Soc Nephrol 2009; 4: 1670-1676
7. Schwab K, Witte DP, Aronow BJ et al. Microarray analysis of focal segmental glomerulosclerosis. Am J Nephrol 2004; 24: 438-447
8. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760 (Pubitemid 351347767)
9. Isaka Y, Fujiwara Y, Ueda N et al. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or plateletderived growth factor gene into the rat kidney. J Clin Invest 1993; 92: 2597-2601
10. Schnaper HW, Jandeska S, Runyan CE et al. TGF-beta signal transduction in chronic kidney disease. Front Biosci 2009; 14: 2448-2465
11. Esposito C, Parrilla B, Cornacchia F et al. The antifibrogenic effect of hepatocyte growth factor (HGF) on renal tubular (HK-2) cells is dependent on cell growth. Growth Factors 2009; 27: 137-180
12. Sugimoto H, Grahovac G, Zeisberg M et al. Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors. Diabetes 2007; 56: 1825-1833
13. Mezzano SA, Barria M, Droguett MA et al. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease. Kidney Int 2001; 60: 1366-1377
14. Myllymaki JM, Honkanen TT, Syrjanen JT et al. Severity of tubulointerstitial inflammation and prognosis in immunoglobulin A nephropathy. Kidney Int 2007; 71: 343-348
15. Platzer C, Ode-Hakim S, Reinke P et al. Quantitative PCR analysis of cytokine transcription patterns in peripheral mononuclear cells after anti-CD3 rejection therapy using two novel multispecific competitor fragments. Transplantation 1994; 58: 264-268
16. Katafuchi R, Vamvakas E, Neelakantappa K et al. Microvascular disease and the progression of IgA nephropathy. Am J Kidney Dis 1990; 15: 72-79
17. Goto M, Wakai K, Kawamura T et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant 2009; 24: 3068-3074
18. Border WA, Noble NA. Interactions of transforming growth factorbeta and angiotensin II in renal fibrosis. Hypertension 1998; 31: 181-188
19. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210
20. Ju W, Eichinger F, Bitzer M et al. Renal gene and protein expression signatures for prediction of kidney disease progression. Am J Pathol 2009; 174: 2073-2085
21. Jafar TH, Stark PC, Schmid CH et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin- converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252
22. Van Es LA, de Heer E, Vleming LJ et al. GMP-17-positive T-lymphocytes in renal tubules predict progression in early stages of IgA nephropathy. Kidney Int 2008; 73: 1426-1433
23. Roberts IS, Cook HT, Troyanov S et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int 2009; 76: 546-556